Genmab
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +59.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 1.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 43.2x | Better than 12% |
| Forward P/E | 34.8x | Better than 14% |
| Price / Sales | 7.8x | Better than 14% |
| P/E vs own 5-yr range | 84th pctl | Better than 22% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 21.2% | Better than 83% |
| Net income CAGR (3Y) | 7.1% | Better than 54% |
| Free cash flow CAGR (3Y) | 29.8% | Better than 74% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 93.6% | Better than 98% |
| Operating margin | 33.6% | Better than 92% |
| Net margin | 25.9% | Better than 86% |
| Return on equity | 17.6% | Better than 74% |
| Return on invested capital | 10.9% | Better than 72% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 51.3% | Better than 100% |
| 6-month return | 88.3% | Better than 99% |
| 12-month return (ex latest month) | 31.4% | Better than 70% |
| Distance below 52-week high | 15.6% | Better than 70% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.0x | Better than 56% |
| Debt to assets | 42.2% | Better than 24% |
| Interest coverage | 20.7x | Better than 83% |
| Free cash flow / net income | 117.4% | Better than 50% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 88.9% | Better than 71% |
| Upside to average target | 27.9% | Better than 46% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 51.35
- Open
- 51.57
- Day range
- 50.24 - 51.72
- Avg price
- 50.88
- Volume
- 2.90M
- Turnover
- 147.50M
- Turnover ratei
- 0.51%
- Volume ratioi
- 0.83
- Amplitudei
- 2.88%
- 52-week rangei
- 23.62 - 59.97
Valuation
- P/Ei
- 32.92
- P/E (TTM)i
- 43.25
- P/Bi
- 4.93
- EPSi
- 1.54
- Book value / shi
- 10.27
- Net profit
- 947.70M
- Net assets
- 6.33B
Share structure
- Market cap
- 31.20B
- Float capi
- 29.01B
- Shares out
- 616.59M
- Float sharesi
- 573.24M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-07-18
15.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.30M net over the window
Short interest
- Shares short
- 9.66M
- % of floati
- 1.57%
- Days to coveri
- 1.24
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Genmab (GMAB)?
Genmab last traded at 50.60. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Genmab's market cap?
About 31.20B.
What is the P/E ratio of Genmab?
The trailing twelve-month P/E is 43.25, above its own 5-year average of 29.46 — toward the top of its historical range (81.43% percentile). See the Valuation tab for the full history.
Does Genmab pay a dividend?
Genmab does not currently pay a regular dividend.
Is Genmab a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 64.57, which implies 27.6% upside from the current price. This is not investment advice.
What is Genmab's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Genmab a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.
Genmab discussion 0 comments